Key facts
- It has raised $100K; the latest was Later Stage VC in Feb 2026.
- Notable investors include N.XT, Northwestern University, The National Institute on Aging (NIA).
- Akava Therapeutics has filed 3 Form Ds with the SEC since 2023, most recently Feb 2025 ($100K sold to 1 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Akava Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Akava Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Akava Therapeutics
Developer of small molecule therapeutics designed to inhibit protein aggregation, inhibit enzymes, and inhibit cancer for a variety of neurodegenerative diseases and cancers. The company's therapeutics is a protein aggregation inhibitor that helps to improve the health of upper motor neurons to degenerate in motor neuron diseases, such as amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), and ALS or frontotemporal lobar degeneration (FTLD), enabling patients to live longer with improved quality of life.
- Sector
- Healthcare
- HQ
- Winnetka, IL, United States
- Website
- akavatx.com/
- Ownership
- Privately Held (backing)
Akava Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Akava Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Akava Therapeutics in its N-PORT filings yet. We sweep new filings monthly.